Analysis of Various Factors Associated With Opioid Dose Escalation in Patients With Cancer Pain

Ryo Sakamoto 1, Atsuko Koyama 1

1. Department of Psychosomatic Medicine, Kindai University Faculty of Medicine, Osakasayama, JPN

Corresponding author: Ryo Sakamoto, ryo-sakamoto@med.kindai.ac.jp

Abstract

Introduction

Pain is one of the most important symptoms in terms of prevalence and a major cause of distress in patients with cancer. Therefore, this study aimed to analyze and identify the factors that influence the worsening of pain in patients with cancer necessitating opioid dose escalation.

Methods

The study was conducted in a single center. This study is a retrospective cohort study of 390 adult cancer patients. The primary endpoint was dose escalation for strong opioids. Adjusted odds ratios (aORs) and their 95% confidence intervals (CIs) were calculated using a logistic regression model to evaluate the relationships of factors with opioid dose escalation for cancer pain.

Results

Polypharmacy was associated with opioid dose escalation (aOR = 2.54, 95% CI = 1.486-4.370, p = 0.001). Conversely, alcohol consumption was associated with a reduced need for dose escalation (aOR = 0.60, 95% CI = 0.376-0.985, p = 0.043).

Conclusion

The results of this study indicate that moderate alcohol consumption does not reduce the efficacy of opioids in patients with cancer pain. Meanwhile, patients receiving polypharmacy may be able to more rapidly alleviate their pain via early opioid dose modification.

Categories: Pain Management, Palliative Care

Keywords: pain, cancer, alcohol consumption, polypharmacy, opioid dose escalation

Introduction

The incidence and incidence rate of cancer patients is increasing from year to year [1]. Globally, it is estimated that 18.1 million people will develop cancer, and 9.6 million died of cancer in 2018. In Japan, 1.01 million people were diagnosed with cancer in 2020, and 379,400 people died of cancer [2]. Although the symptoms of cancer vary widely, cancer pain is one of the most frequent and severe symptoms experienced by patients requiring palliative care [3]. Cancer pain is present in 39.3% of patients after curative treatment, 55% of patients during antineoplasic treatment, 66.4% of patients with advanced, metastatic, or terminal disease, and 50.7% of all patients with cancer. Moderate to severe pain has also been reported in 38% of patients with cancer [4,5]. Morphine is recommended as the first-line treatment for controlling moderate to severe cancer pain [6]. According to the World Health Organization guidelines for the pharmacological treatment of cancer pain published in 2019, cancer pain is classified by neural mechanisms as either nociceptive or neuropathic. However, not all types of pain in patients with cancer are solely related to the tumor, and thus, they cannot automatically be defined as cancer pain. A large prospective study conducted on patients with cancer illustrated that approximately 17% of the pain perceived by the patients was caused by antineoplasic treatments and approximately 10% was attributable to other etiologies unrelated to cancer [7]. Among patients with cancer pain, more than 40% experience inadequate pain relief and remain potentially undertreated [8]. Cancer pain can potentially alter the quality of life (QOL) of patients [9], and it has physical, psychological, and emotional effects on daily and social life [10]. In patients with cancer pain, it is critical to identify whether the perceived pain is caused by treatment or other factors in order to provide necessary treatment. Exploring the factors that contribute to worsening cancer pain can facilitate the development of countermeasures to prevent future worsening of pain. We believe that if pain can be controlled at an early stage, patients’ motivation to continue treatment and their QOL can be improved. Therefore, this study investigated the factors resulting in opioid dose modification because of cancer pain at our hospital.
Materials And Methods

Study design
This study was a retrospective investigation of patients with cancer pain who were started on strong opioids and required dose escalation within one month. Strong opioids are defined by the WHO Cancer pain relief. Eligible patients had histories of surgery, pharmacotherapy, radiotherapy, and palliative treatment.

Participants
From October 2017 to September 2020, we conducted a retrospective study using the electronic medical records of eligible cancer pain patients who visited a hospital affiliated with Kindai University and were prescribed strong opioids for the first time at our hospital. Patients with missing data in their medical records were excluded. After excluding three patients with missing study items in the electronic medical record, 390 patients were included in the study.

Demographic information
Background information included age, sex, and comorbidities; bone metastasis; performance status; the receipt of analgesics other than opioids; the use of psychotropic drugs, chemotherapy, radiotherapy, or polypharmacy; residential status; area of residence; smoking; and alcohol history. Polypharmacy was defined as the concurrent use of five or more drugs [11], excluding cancer drugs, because many patients were undergoing active cancer treatment. This study was approved by the Kindai University Hospital Clinical Research Ethics Review Committee (approval number 2020-268). The research process and the preparation of this paper were guided by the Declaration of Helsinki’s ethical principles for medical research involving human subjects.

Endpoints
The primary endpoint was the dose escalation of strong opioids. The analyzed strong opioids were morphine, oxycodone, hydromorphone, tapentadol, fentanyl, and methadone. The primary study endpoint was baseline opioid dose escalation within one month. Dose titration was defined as an addition to the originally prescribed baseline daily opioid dose. The decision to increase the opioid dose was made by the attending physician based on patient complaints. The approximate range of opioid escalation was 30%-50% per dose. In the study’s definition of increased opioid dosage, the number of titrations within a period of time was irrelevant. The evaluation period was within one month. The reason for this is that follow-up should occur as early as possible to assess the need for an opioid dosage increase [12].

Statistical analyses
Each drug was determined using Microsoft Excel version 16.0 (Microsoft Corp., Redmond, WA, USA). A comparison of the opioid dose escalation group and no opioid dose escalation group was performed using Welch’s t-test. To evaluate the relationships between variables and opioid dose escalation for cancer pain, adjusted odds ratios (aORs) and their 95% confidence intervals (CIs) were calculated using a logistic regression model. Multiple logistic regression was performed with adjustment for all potential confounders listed in the endpoints. All statistical analyses were performed using SPSS version 25 (SPSS, Inc., Chicago, IL, USA).

Results
The characteristics of the target patients are presented in Table 1. The included patients had a mean age of 66.2 ± 11.8 years, and 62% of the subjects were male. The most common type of cancer was lung cancer (23%), followed by head and neck cancer (15%) and colorectal cancer (9%). Of the patients, 31% had bone metastases from cancer, 72% had a performance status of 0-2, 49% were receiving chemotherapy, and 13% were receiving radiotherapy. Meanwhile, 42% of the patients required opioid dose escalation.

| Age, mean (standard deviation; range) | 66.2 (11.8; 27-93) |
|--------------------------------------|--------------------|
| Sex (%)                              |                    |
| Men                                  | 243 (62.3)         |
| Women                                | 147 (37.7)         |
| Cancer                               |                    |
| Primary site (%)                     |                    |
| Lung                                 | 92 (23.5)          |
| Location                        | Count (Percentage) |
|--------------------------------|--------------------|
| Head and neck                  | 59 (15.1)          |
| Duodenum, colon, rectum        | 36 (9.2)           |
| Pancreatic                     | 34 (8.7)           |
| Esophagus                      | 26 (6.6)           |
| Breast                         | 22 (5.6)           |
| Stomach                        | 19 (4.8)           |
| Hepatobiliary                  | 19 (4.8)           |
| Urinary system                 | 19 (4.8)           |
| Unknown primary                | 12 (3)             |
| Uterus and ovaries             | 10 (2.5)           |
| Blood                          | 6 (1.5)            |
| Thyroid                        | 6 (1.5)            |
| Malignant pleural mesothelioma | 6 (1.5)            |
| Other                          | 24 (6.1)           |
| Bone metastasis                |                    |
| Yes                            | 123 (31.5)         |
| No                             | 267 (68.5)         |
| Performance status (%)         |                    |
| 0-2                            | 282 (72.3)         |
| 3-4                            | 108 (27.7)         |
| Opioid base-up (within one month) |                |
| Yes                            | 167 (42.8)         |
| No                             | 223 (57.2)         |
| Chemotherapy                   |                    |
| Yes                            | 192 (49.2)         |
| No                             | 198 (50.8)         |
| Radiotherapy                   |                    |
| Yes                            | 52 (13.3)          |
| No                             | 338 (86.7)         |

**TABLE 1: Patient characteristics**

The comorbidities, medications, and social backgrounds of the patients are presented in Table 2. Comorbidities were found in 70.5% of the patients, and 70.2% of the patients received polypharmacy. Analgesics other than opioids were administered to 78.4% of the patients, and 28.9% of the patients received psychotropic drugs. In total, 15.6% of the patients lived alone, and 74.8% of the patients resided in municipalities surrounding Osakasayama City. Smoking and drinking were recorded for 21% and 38.2% of the patients, respectively.
|                                | n (%)     |
|--------------------------------|-----------|
| **Comorbidity**                |           |
| Yes                            | 275 (70.5) |
| No                             | 115 (29.5) |
| **Polypharmacy**               |           |
| Yes                            | 274 (70.2) |
| No                             | 116 (29.8) |
| **Analgesics (non-opioid)**    |           |
| Yes                            | 306 (78.4) |
| No                             | 84 (21.6)  |
| **Psychotropic**               |           |
| Yes                            | 113 (28.9) |
| No                             | 277 (71.1) |
| **Household**                  |           |
| Solitary life                  | 61 (15.6)  |
| Gregariousness                 | 329 (84.4) |
| **Distance to the hospital**   |           |
| Surrounding municipalities     | 292 (74.8) |
| More remote than nearby        | 98 (25.2)  |
| **Smoking**                    |           |
| Yes                            | 82 (21)    |
| No                             | 308 (79)   |
| **Drinking**                   |           |
| Yes                            | 149 (38.2) |
| No                             | 241 (61.8) |

**TABLE 2: Patient's drug and social background**

The comparison of drug doses between the groups with and without increasing opioid doses is shown in Table 3. Oral morphine equivalent daily dose (OMEDD) was converted for each opioid using the equivalence conversion table as a reference [13-15]. The results of the t-test showed that the differences in the mean daily doses of OMEDD (p = 0.0033), morphine (po) (p = 0.0002), and hydromorphone (po) (p = 0.0027) were significant.
| Drugs (mg)                      | Opioid dose escalation group (n = 167) | No opioid dose escalation group (n = 223) | p-value |
|--------------------------------|----------------------------------------|------------------------------------------|---------|
| OMEDD                          | 28.525 (48.499)                        | 34.556 (63.561)                          | 0.033   |
| Each strong opioid (daily dose)|                                        |                                          |         |
| Morphine (po)                  | 23.333 (4.714)                         | 32.857 (12.777)                         | 0.002   |
| Morphine (iv)                  | None                                   | 25                                       | ns      |
| Oxycodone (po)                 | 29.150 (28.095)                        | 27.733 (37.249)                         | ns      |
| Oxycodone (iv)                 | 22.916 (12.112)                        | 17.5                                     | ns      |
| Hydromorphone (po)             | 4.00 (11.25)                           | 7.866 (11.086)                          | 0.027   |
| Fentanyl (td)                  | 1.545 (1.157)                          | 1.604 (1.324)                           | ns      |
| Fentanyl (iv)                  | 0.12                                   | 1.200 (1.080)                           | ns      |
| Tapentadol                     | 45                                     | 135.714 (58.028)                        | ns      |
| Methadone                      |                                        | None                                     | ns      |
| Each analgesic (daily dose)    |                                        |                                          |         |
| NSAIDs (po)                    |                                        |                                          |         |
| Loxoprofen                     | 172.881 (27.249)                       | 170.769 (34.072)                        | ns      |
| Celecoxib                      | 322.222 (97.499)                       | 254.544 (89.072)                        | ns      |
| Diclofenac sodium              | 37.500 (12.500)                        | 50.000 (22.360)                         | ns      |
| Etodolac                       | 400                                    | 400                                      | ns      |
| Naproxen                       | 200                                    | 400.000 (167.332)                       | ns      |
| NSAIDs (iv)                    |                                        |                                          |         |
| Flurbiprofen axetil            | 150                                    | 150                                      | ns      |
| Acetaminophen                  | 2218.220 (843.781)                     | 2098.928 (808.100)                      | ns      |
| Pregabalin                     | 151.250 (108.245)                      | 147.727 (88.840)                        | ns      |
| Mirogabalin                    | 13.750 (9.601)                         | 14.000 (8.602)                          | ns      |
| Duloxetine                     | 44.000 (14.966)                        | 33.333 (9.423)                          | ns      |
| Amitriptyline hydrochloride (po)| 25                                     | None                                     | ns      |
| Corticosteroids (po)           |                                        |                                          |         |
| Betamethasone                  | 2                                      | 1.833 (0.372)                           | ns      |
| Dexamethasone                  | 4.250 (3.750)                          | 1                                       | ns      |
| Prednisolone                   | 16.888 (13.135)                        | 7.000 (2.449)                           | ns      |
| Corticosteroids (iv)           |                                        |                                          |         |
| Betamethasone                  | 6 (2.000)                              | 6.181 (1.991)                           | ns      |
| Dexamethasone                  | 7.333 (3.023)                          | 7.228 (2.414)                           | ns      |

**TABLE 3: Comparison of drug dose between the opioid dose escalation group and the no opioid dose escalation group**

Drugs are shown as means and standard deviations (±SD).

SD, standard deviation; OMEDD, oral morphine equivalent daily dose; po, oral; iv, intravenous; td, transdermal; ns, not significant
Table 4 presents the results of the regression analysis for patients requiring dose escalation. Polypharmacy (aOR = 2.54, 95% CI = 1.486-4.370, p = 0.001) was associated with opioid dose escalation. Conversely, alcohol consumption was associated with a reduced need for dose modification (aOR = 0.60, 95% CI = 0.376-0.985, p = 0.043). No other factors were associated with opioid dose escalation.
| Smoking | Drking | Yes | No | Reference | Reference |
|---------|---------|-----|----|----------|----------|
| More remote than nearby | 0.80 | 0.503-1.285 | 0.036 | 1.40 | 0.849-2.322 | 0.186 |
| Smoking | No | 0.59 | 0.355-0.991 | 0.046 | 0.57 | 0.325-1.007 | 0.053 |
| Drinking | Yes | 0.54 | 0.354-0.829 | 0.005 | 0.60 | 0.376-0.985 | 0.043 |

**TABLE 4: Odds ratios and 95% confidence intervals for factors influencing opioid dose escalation for cancer pain**

OR, odds ratio; CI, confidence interval

**Discussion**

The first important finding of this study was that drinking habits may not increase the need for opioid dose modification in patients with cancer pain. Previous studies have reported that chronic pain often results in the concurrent use of alcohol and opioids and that excessive alcohol consumption has a negative impact on pain [16]. The periaqueductal gray (PAG), also known as the pain circuit, plays a central role in nociception, and it has been implicated in the pathogenesis of anticipated pain and perceived pain [17,18]. PAG also influences pain sensitivity associated with problematic alcohol consumption and alcohol-induced changes in brain mechanisms that underpin PAG-mediated stress responses and pain transmission [19-21]. Excessive alcohol consumption is associated with pain, often through alcohol-induced changes in brain mechanisms that support PAG-mediated stress responses and pain transmission [22]. Excessive alcohol intake has negative effects on pain; however, it has also been suggested that PAG, which is involved in the pain circuitry, and the medial orbitofrontal cortex, which is involved in the reward circuitry, act antagonistically to modulate alcohol expectancy and control drinking behavior [23]. In fact, it has been reported that patients with chronic non-cancer pain are less likely to drink alcohol, and alcohol consumption is further reduced in opioid users [24]. Thus, it is possible that drinking habits that do not result in excessive alcohol consumption, as indicated by our findings, may have some beneficial effects on patient QOL by stimulating the reward system without exerting a negative effect on pain, thereby slowing the worsening of pain. In addition, the study results suggested that polypharmacy may affect the need for opioid dose escalation for cancer pain. Polypharmacy is common among prefrail and frail adults [25]. Patients with cancer experience fatigue associated with cancer progression, treatment, and other factors, and this fatigue can exacerbate pain [23]. Moreover, polypharmacy has also been found to be associated with poor health-related QOL [26]. Patients’ subjective health conditions range from disorders of mental health and vitality to pain [27]. Thus, a decrease in health-related QOL may be associated with worsening pain. These factors may have also led to an increase in the dose of strong opioids.

Five limitations of this study must be mentioned. First, all patients were recruited from a single institution. According to Japanese national cancer incidence data, men are more likely to develop stomach cancer, trachea, bronchus, and lung (TBL) cancer, and colorectal cancer, whereas women are more likely to develop breast cancer, colorectal cancer, and stomach cancer [28]. According to global cancer incidence data, men are more likely to develop skin cancer, TBL cancer, and prostate cancer, whereas women are more likely to develop non-melanoma skin cancer, breast cancer, and colorectal cancer [29]. Although these rates differ slightly from those of the study population, all of these cancer types were represented in the study, and it is unlikely that these differences affected the validity of the results. Second, the timing of opioid dose escalation was based on the date on which strong opioids were first prescribed in our hospital. Kindai University Hospital is a regional center for cancer treatment that has a system through which patients who require cancer treatment are referred or who require cancer treatment are referred for a consultation, but some patients are prescribed strong opioids prior to visiting the hospital. In other words, opioids are used in conditions where there is an acute need for them, and their use in non-acute care has not been evaluated and is a subject for future study. Third, the criteria for determining the use of polypharmacy were unclear, as it is difficult to determine whether a prescription is appropriate simply by checking patients’ medical records. It is also difficult to determine the actual level of adherence to medication. In the future, it will be necessary to use tools that enable comprehensive assessments of polypharmacy to determine both the number of medications and whether the patient is truly polyphasic [30]. Fourth, alcohol intake was only interviewed as “yes” or “no,” so it is not known how much alcohol is consumed. Finally, the results of the medical records made it difficult to classify the nature of the pain. The classification was difficult because some attending physicians did not describe nociceptive, somatic, or neuropathic pain.
Conclusions
The results suggest that drinking habits may not increase the need for opioid dose modification and that polypharmacy may influence opioid dose escalation for cancer pain. The findings of this study may provide clues to preventing the worsening of cancer pain in the future. However, because of the limitations described in this study, further evaluation and examination of the factors are necessary in the future.

Additional Information
Disclosures
Human subjects: Consent was obtained or waived by all participants in this study. Kindai University Hospital Clinical Research Ethics Review Committee issued approval 2020-268. Animal subjects: All authors have confirmed that this study did not involve animal subjects or tissue. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

Acknowledgements
We thank Joe Barber Jr., PhD, from Edanz Group (https://en-author-services.edanz.com/ac) for editing a draft of this manuscript.

References
1. Ferlay J, Colombet M, Sorjomataram I, et al.: Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. 2019, 144:1941-53. 10.1002/ijc.31937
2. National Cancer Center: Cancer statistics in Japan-2021. (2021). Accessed: January 18, 2022: https://ganjojou.ip/public/qa_link/report/statistics/pdf/cancer_statistics_2021.pdf.
3. World Health Organization: Palliative care. (2022). Accessed: January 18, 2022: https://www.who.int/health-topics/palliative-care.
4. van den Beuken-van Everdingen MH, Hochstenbach LM, Joosten EA, Tjän-Heijnen VC, Janssen DI: Update on prevalence of pain in patients with cancer: systematic review and meta-analysis. J Pain Symptom Manage. 2016, 51:1070-1090.e9. 10.1016/j.jpainsymman.2015.12.340
5. World Health Organization: WHO guidelines for the pharmacological and radiotherapeutic management of cancer pain in adults and adolescents. (2019). Accessed: January 18, 2022: https://www.who.int/publications/i/item/9789241550590.
6. Grond S, Zech D, Diefenbacher C, Radbruch L, Lehmann KA: Assessment of cancer pain: a prospective evaluation in 2266 cancer patients referred to a pain service. Pain. 1996, 64:107-14. 10.1016/0304-3959(95)00076-3
7. van den Beuken-van Everdingen MH, de Rijke M, Kessels AG, Schouten HC, van Kleef M, Patijn J: Prevalence of pain in patients with cancer: a systematic review of the past 40 years . Ann Oncol. 2007, 18:1457-49. 10.1093/annonc/mdm036
8. Deandrea S, Montanari M, Moja L, Apolone G: Prevalence of undertreatment in cancer pain. A review of published literature. Ann Oncol. 2008, 19:1985-91. 10.1093/annonc/mdn419
9. Rodriguez C, Ji M, Wang HL, Padhyta Y, McMillan SC: Cancer pain and quality of life. J Hosp Palliat Nurs. 2019, 21:116-23. 10.1097/JHPN.0000000000000507
10. Ahmad I, Ahmed MM, Afrasiyab MF, Naeem A, Tasleem A, Ahmed M, Farooqi MS: Pain management in metastatic bone disease: a literature review. Cureus. 2018, 10:e5286. 10.7759/cureus.5286
11. Viktil KK, Blix HS, Moger TA, Reikvam A: Polypharmacy as commonly defined is an indicator of limited value in the assessment of drug-related problems. Br J Clin Pharmacol. 2007, 63:187-95. 10.1111/j.1365-2125.2006.02744.x
12. Bruea E, Paice JA: Cancer pain management: safe and effective use of opioids . Am Soc Clin Oncol Educ Book. 2015, e595-9. 10.14354/EdBook_AM.2015.35.e595
13. Walker PW, Palla S, Pei BL, et al.: Switching from methadone to a different opioid: what is the equianalgesic dose ratio? J Palliat Med. 2008, 11:1103-8. 10.1089/jpm.2007.0288
14. Mercadante S, Porzio G, Aielli F, et al.: Opioid switching from and to tapentadol extended release in cancer patients: conversion ratio with other opioids. Curr Med Res Opin. 2015, 29:661-6. 10.1185/03007995.2015.791617
15. Mercadante S, Caraceni A: Conversion ratios for opioid switching in the treatment of cancer pain: a systematic review. Palliat Med. 2011, 25:304-15. 10.1177/0269216311406577
16. Wiktorski K, Vowles KE: Alcohol and opioid use, co-use, and chronic pain in the context of the opioid epidemic: a critical review. Alcohol Clin Exp Res. 2018, 42:278-88. 10.1111/acel.13594
17. Wager TD, Rilling JK, Smith EE, et al.: Placebo-induced changes in FMRI in the anticipation and experience of pain. Science. 2004, 305:1162-7. 10.1126/science.1095065
18. Sprenger C, Finsterbusch J, Böckel C: Spinal cord-midbrain functional connectivity is related to perceived pain intensity: a combined spino-cortical FMRI study. J Neurosci. 2015, 35:2448-57. 10.1523/JNEUROSCI.4897-14.2015
19. Heinricher MM, Martenson ME, Neubert MJ: Prostaglandin E2 in the midbrain periaqueductal gray produces hyperalgesia and activates pain-modulating circuitry in the rostral ventromedial medulla. Pain. 2004,
20. Lovick TA: Pro-nociceptive action of cholecystokinin in the periaqueductal grey: a role in neuropathic and anxiety-induced hyperalgesic states. Neurosci Biobehav Rev. 2008, 32:852-62. 10.1016/j.neubiorev.2008.01.005

21. Robins MT, Heinricher MM, Rhybinin AE: From pleasure to pain, and back again: the intricate relationship between alcohol and nociception. Alcohol Alcohol. 2019, 54:625-58. 10.1093/alcalc/agz067

22. Egli M, Koob GF, Edwards S: Alcohol dependence as a chronic pain disorder. Neurosci Biobehav Rev. 2012, 36:2179-92. 10.1016/j.neubiorev.2012.07.010

23. Le TM, Zhornitsky S, Zhang S, Li CR: Pain and reward circuits antagonistically modulate alcohol expectancy to regulate drinking. Transl Psychiatry. 2020, 10:220. 10.1038/s41398-020-00909-z

24. Ekholm O, Granberg M, Pruckmann V, Sjogren F: Alcohol and smoking behavior in chronic pain patients: the role of opioids. Eur J Pain. 2009, 13:606-12. 10.1016/j.ejpain.2008.07.006

25. Palmer K, Villani ER, Vetrano DL, et al.: Association of polypharmacy and hyperpolypharmacy with frailty states: a systematic review and meta-analysis. Eur Geriatr Med. 2019, 10:9-36. 10.1007/s41999-018-0124-5

26. Fincke BG, Miller DR, Spiro A 3rd: The interaction of patient perception of overmedication with drug compliance and side effects. J Gen Intern Med. 1998, 13:182-5. 10.1046/j.1525-1497.1998.00053.x

27. Cell D: Quality of life: concepts and definition. J Pain Symptom Manage. 1994, 9:186-92. 10.1016/0885-3924(94)90129-5

28. Hori M, Matsuda T, Shibata A, Katanoda K, Sobue T, Nishimoto H: Cancer incidence and incidence rates in Japan in 2009: a study of 32 population-based cancer registries for the Monitoring of Cancer Incidence in Japan (MCII) project. Jpn J Clin Oncol. 2015, 45:884-91. 10.1093/jjco/hyu088

29. Fitzmaurice C, Akinyemiju TF, Al Lami FH, et al.: Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2016: a systematic analysis for the global burden of disease study. JAMA Oncol. 2018, 4:1533-68. 10.1001/jamaoncol.2018.2706

30. Masumoto S, Sato M, Momio K, et al.: Development of medication regimen complexity index: Japanese version and application in elderly patients. Int J Clin Pharm. 2021, 43:858-63. 10.1007/s11096-020-01185-z